Abstract
Old people are at high risk of developing and dying from pulmonary infections like tuberculosis (TB), but they are few studies and particularly in Hispanics. To address these gaps, we sought to identify host factors associated with TB and adverse treatment outcomes in old Hispanics by conducting a secondary analysis of TB surveillance data from Tamaulipas, Mexico (2006-2013; n=8,381). Multivariable logistic regressions were assessed for the elderly (ELD, ≥65 years) when compared to young (YA, 18 to 39 years) and middle-aged adults (MAA, 40 to 64 years). We found that the ELD had features associated with a less complicated TB (e.g. less extra-pulmonary TB, abandoning of treatment or having drug resistant TB), and yet, were more likely to die during TB treatment (adj-OR 3.9, 95% 2.5, 5.25). Among the elderly, excess alcohol use and low BMI increased their odds of death, while diabetes and BCG vaccination were protective. These data suggest that old people share some, but not all the risk factors for adverse TB treatment outcomes, when compared with younger adults. Furthermore, even though old age in itself is an important predictor of death during TB, the elderly are not prioritized by the World Health Organization for latent TB infection screening and treatment during contact investigations. We propose the inclusion of the elderly as a high-risk group in TB management guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the National Institute On Aging of the National Institutes of Health [P01-AG051428 to BIR R01-AG082341-01 to BIR]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Permission to conduct this retrospective data analysis was granted by the IRBs from the University of Texas Health Science Center Houston (HSC-SPH-15-0489), and the Comité de Investigación de la Secretaría de Salud de Tamaulipas (076/2015/CEI)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Original datasets used for analysis of the findings presented in this manuscript are available upon request.
